1. McGovern D, Williams SP, Parsons K, Farrah TE, Gallacher PJ, Miller-Hodges E, et al. 2020; Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford). 59:1076–83. DOI:
10.1093/rheumatology/kez388. PMID:
31794032.
Article
7. Venetsanopoulou AI, Pelechas E, Voulgari PV, Drosos AA. 2020; The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 40:1181–91. DOI:
10.1007/s00296-020-04616-2. PMID:
32524301.
Article
8. Sarkissian T, Beyenne J, Feldman B, Adeli K, Silverman E. 2006; The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum. 54:1283–90. DOI:
10.1002/art.21748. PMID:
16575849.
Article
9. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. 2007; Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 66:222–7. DOI:
10.1136/ard.2006.054593. PMID:
16901958. PMCID:
PMC1798520.
Article
11. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. 2009; Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 68:1827–32. DOI:
10.1136/ard.2008.101279. PMID:
19054820.
Article
13. Ahn SS, Kim JO, Yoon T, Song JJ, Park YB, Lee SW, et al. 2019; Serum aminoacyl-tRNA synthetase-interacting multifunctional protein-1 can predict severe antineutrophil cytoplasmic antibody-associated vasculitis: a pilot monocentric study. Biomed Res Int. 2019:7508240. DOI:
10.1155/2019/7508240. PMID:
31236412. PMCID:
PMC6545776.
Article
14. Wallace ZS, Fu X, Liao K, Kallenberg CGM, Langford CA, Merkel PA, et al. 2019; Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 71:1879–87. DOI:
10.1002/art.41006. PMID:
31162829. PMCID:
PMC6944270.
Article
16. Marques LR, Diniz TA, Antunes BM, Rossi FE, Caperuto EC, Lira FS, et al. 2018; Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol. Front Physiol. 9:526. DOI:
10.3389/fphys.2018.00526. PMID:
29867567. PMCID:
PMC5962737.
Article
18. Wang SH, Yuan SG, Peng DQ, Zhao SP. 2012; HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis. 225:105–14. DOI:
10.1016/j.atherosclerosis.2012.07.029. PMID:
22862966.
Article
19. Wang Y, Lu S, Zhang G, Wu S, Yan Y, Dong Q, et al. 2018; Anti-inflammatory effects of HDL in mice with rheumatoid arthritis induced by collagen. Front Immunol. 9:1013. DOI:
10.3389/fimmu.2018.01013. PMID:
29867985. PMCID:
PMC5958197.
Article
21. Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A, et al. 2009; Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol. 27:79–83. PMID:
19327233.
22. Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L. 2013; Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis. 72:1273–9. DOI:
10.1136/annrheumdis-2013-203255. PMID:
23606701.
Article
23. Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. 2016; ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 12:570–9. DOI:
10.1038/nrrheum.2016.123. PMID:
27464484.
Article
25. Hilhorst M, van Paassen P, Tervaert JW. Limburg Renal Registry. 2015; Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol. 26:2314–27. DOI:
10.1681/ASN.2014090903. PMID:
25956510. PMCID:
PMC4587702.
Article
26. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. 2008; Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58:2908–18. DOI:
10.1002/art.23800. PMID:
18759282. PMCID:
PMC2754705.
Article
27. Yoo J, Kim HJ, Ahn SS, Jung SM, Song JJ, Park YB, et al. 2017; Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis. Clin Exp Rheumatol. 35 Suppl 103:111–8. PMID:
28339364.
29. Subramanian S, Trence DL. 2007; Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am. 36:891–905. DOI:
10.1016/j.ecl.2007.07.003. PMID:
17983927.